BeOne Medicines registers Phase 2 tislelizumab dosing study in Japanese ESCC patients
BeOne Medicines listed a Phase 2 trial testing two tislelizumab dosing schedules with FOLFOX chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma.
BeOne Medicines had one registry update of note this period.
- A Phase 2 study will test tislelizumab given on alternative dosing schedules plus chemotherapy as first-line treatment in Japanese patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma.1 The study is listed as recruiting, with the study set to enroll approximately 30 participants in Japan with ESCC1 across two dosing arms, tislelizumab every 2 weeks or every 4 weeks, each paired with FOLFOX chemotherapy.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.